Rucaparib

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 708 publications

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA.

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA.

Journal: Cancers

Published: July 06, 2026

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Journal: Future oncology (London, England)

Published: June 18, 2026

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Synthesis and Preliminary Evaluation of the 211At-Labeled PARP Inhibitor [211At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic.

Journal: Molecular pharmaceutics

Published: June 08, 2026

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

From dual inhibition to precision selectivity: the molecular rationale and clinical evolution of next-generation PARP1-selective inhibitors in solid tumors.

Journal: Frontiers in oncology

Published: May 29, 2026

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis.

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis.

Journal: Frontiers in oncology

Published: May 08, 2026

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: April 30, 2026

Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP/EZH2 inhibitors for robust prostate cancer treatment.

Rethinking the PSMA-mediated tumor targeting of nanocarrier and potentiating co-delivery of PARP/EZH2 inhibitors for robust prostate cancer treatment.

Journal: Biomaterials

Published: April 29, 2026

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors.

Journal: RSC advances

Published: April 10, 2026

Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer.

Synthetic lethality between PBRM1 deficiency and PARP inhibitors: exploiting G2/M checkpoint arrest in colorectal cancer.

Journal: Molecular medicine (Cambridge, Mass.)

Published: April 08, 2026

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer.

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer.

Journal: PloS one

Published: April 02, 2026

Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis.

Novel Class I HDAC Inhibitors Sensitize Ovarian Cancer Cells for Cisplatin and Niraparib via an HDAC3-SLFN11 Axis.

Journal: ACS chemical biology

Published: March 31, 2026

The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from Quebec.

The Impact of Pathogenic Variants of BRCA1, BRCA2 and Other DNA-Repair Genes on the Survival Benefits Conferred by PARP Inhibitors - Single Center Experience from Quebec.

Journal: Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC

Published: March 27, 2026

Showing 1-12 of 708

Last Updated: 09/26/2026